thyroid cancer

News

FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations

12/01/2020

Journal of Clinical Pathways

Guideline Updates

NCCN Updates Clinical Practice Guideline for Thyroid Carcinomas

06/22/2020

The National Comprehensive Cancer Network (NCCN) recently released an updated version of its clinical practice guideline for thyroid carcinomas. Multiple global updates are included throughout the guideline,...

The...

06/22/2020

Journal of Clinical Pathways

Research in Review

Vemurafenib Improves Response in Patients With Thyroid Cancer

07/28/2016

JCP Editors

Vemurafenib, a drug originally approved for use in patients with BRAF-positive melanoma, has also shown promising anti-tumor activity in some patients harboring this same mutation in thyroid cancer, according to the...

...

07/28/2016

Journal of Clinical Pathways